- Trials with a EudraCT protocol (22)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
22 result(s) found for: Developmental Toxicity.
Displaying page 1 of 2.
EudraCT Number: 2019-002979-34 | Sponsor Protocol Number: LTFU-ABO-102 | Start Date*: 2020-05-18 | |||||||||||
Sponsor Name:Abeona Therapeutics Inc | |||||||||||||
Full Title: A Long-term Follow-up Study of Patients with MPS IIIA from Gene Therapy Clinical Trials Involving the Administration of ABO-102 (scAAV9.U1a.hSGSH) | |||||||||||||
Medical condition: MPS IIIA is a devastating lysosomal storage disease, caused by a Nsulfoglucosamine sulfohydrolase gene defect. Infants with MPS IIIA appear normal at birth, but the disease is relentlessly progress... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000504-42 | Sponsor Protocol Number: ABT-003 | Start Date*: 2019-05-21 | |||||||||||
Sponsor Name:Abeona Therapeutics Inc | |||||||||||||
Full Title: A Phase I/II Open Label, Single-dose, Gene Transfer Study of scAAV9.U1a.hSGSH (ABO-102) in Patients with Middle and Advanced Phases of MPS IIIA Disease | |||||||||||||
Medical condition: MPS IIIA is a devastating lysosomal storage disease, caused by a Nsulfoglucosamine sulfohydrolase gene defect. Infants with MPS IIIA appear normal at birth, but the disease is relentlessly progress... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003904-21 | Sponsor Protocol Number: ABT-001 | Start Date*: 2016-08-01 |
Sponsor Name:Abeona Therapeutics Inc | ||
Full Title: Phase I/II gene transfer clinical trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA | ||
Medical condition: MPS IIIA is a devastating lysosomal storage disease, caused by a N-sulfoglucosamine sulfohydrolase gene defect. Infants with MPS IIIA appear normal at birth, but the disease is relentlessly progres... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001411-39 | Sponsor Protocol Number: ABT-002 | Start Date*: 2018-09-04 |
Sponsor Name:Abeona Therapeutics Inc | ||
Full Title: Phase I/II gene transfer clinical trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB | ||
Medical condition: MPS IIIB is a devastating lysosomal storage disease, caused by a N-α-acetylglucosaminidase (NAGLU) gene defect. Infants with MPS IIIB appear normal at birth, but the disease is relentlessly progre... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) FR (Prematurely Ended) GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002051-42 | Sponsor Protocol Number: R119861 | Start Date*: 2019-10-25 | |||||||||||
Sponsor Name:University of Manchester | |||||||||||||
Full Title: A phase I-II, study of autologous CD34+ haematopoietic stem cells transduced ex vivo with CD11b lentiviral vector encoding for human SGSH in patients with mucopolysaccharidosis type IIIA (MPS IIIA,... | |||||||||||||
Medical condition: MPS IIIA, mucopolysaccharidosis type IIIA | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002936-97 | Sponsor Protocol Number: LTFU-ABO-101 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Abeona Therapeutics Europe SL. | |||||||||||||
Full Title: A Long-term Follow-up Study of Patients with MPS IIIB from Gene Therapy Clinical Trials Involving the Administration of ABO-101 (rAAV9.CMV.hNAGLU) | |||||||||||||
Medical condition: MPS IIIB is a devastating lysosomal storage disease, caused by a N-α-acetylglucosaminidase (NAGLU) gene defect. Infants with MPS IIIB appear normal at birth, but the disease is relentlessly progres... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003400-39 | Sponsor Protocol Number: NGLU-CL02 | Start Date*: 2014-07-15 | ||||||||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously | ||||||||||||||||||
Medical condition: Mucopolysaccharidosis III, type B (MPS IIIB), Sanfilippo B | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Temporarily Halted) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003031-35 | Sponsor Protocol Number: R04049 | Start Date*: 2015-11-20 | |||||||||||
Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust | |||||||||||||
Full Title: A Single Centre Study Investigating the Safety and Efficacy of an Immune Modulation Regimen in Mitigating the Alloimmune Response to Intravenous Laronidase in Infants With Severe Mucopolysaccharido... | |||||||||||||
Medical condition: Severe Mucopolysaccharidosis Type I (Hurler syndrome, MPS IH) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002796-35 | Sponsor Protocol Number: C4491011 | Start Date*: 2021-01-07 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Vupanorsen (PF 07285557) in Statin-Treated Participan... | |||||||||||||
Medical condition: dyslipidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002113-48 | Sponsor Protocol Number: CRAD001M2302 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized double-blind, placebo-controlled study of RAD001 in the treatment of Angiomyolipoma in patients with either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) | |||||||||||||
Medical condition: Angiomyolipoma in patients with either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) NL (Completed) GB (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000599-40 | Sponsor Protocol Number: KH176-202 | Start Date*: 2019-10-23 |
Sponsor Name:Khondrion B.V. | ||
Full Title: A Phase IIb double-blind, randomised, placebo-controlled, multi-centre, confirmative three-way cross-over study on cognitive function with two doses of KH176 in subjects with a genetically confirme... | ||
Medical condition: A genetically confirmed mitochondrial desoxyribonucleic acid (DNA) transfer ribonucleic acid (tRNA)Leu(UUR) m.3243A>G mutation (including but not limited to MELAS, MIDD and mixed compositions). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) DE (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-000602-18 | Sponsor Protocol Number: BMT-CTN#1301 | Start Date*: 2016-09-26 | |||||||||||
Sponsor Name:National Heart, Lung, and Blood Institute (NHLBI) | |||||||||||||
Full Title: A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus Host-Disease | |||||||||||||
Medical condition: Acute Leukemia in morphologic complete remission Myelodisplasia with less than 5% blasts in the marrow and no circulating blasts | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003124-16 | Sponsor Protocol Number: KH176-204 | Start Date*: 2021-01-12 |
Sponsor Name:Khondrion B.V. | ||
Full Title: A randomized placebo controlled, double-blind phase II study to explore the safety, efficacy and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease. | ||
Medical condition: Genetically confirmed mitochondrial disease | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002378-30 | Sponsor Protocol Number: A3921210 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | |||||||||||||
Medical condition: MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) BE (Ongoing) DE (Ongoing) SK (Completed) HU (Ongoing) FI (Ongoing) ES (Ongoing) NL (Ongoing) PL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001361-27 | Sponsor Protocol Number: ICR-CTSU/2015/10054 | Start Date*: 2016-09-21 | |||||||||||
Sponsor Name:The Institute of Cancer Research | |||||||||||||
Full Title: CTC-STOP: Utilising Circulating Tumour Cell (CTC) Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer. | |||||||||||||
Medical condition: Advanced Castration Resistant Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000832-23 | Sponsor Protocol Number: KH176-203 | Start Date*: 2021-07-12 |
Sponsor Name:Khondrion B.V. | ||
Full Title: A Phase IIb open-label, multi-centre, extension study to explore the long-term safety and efficacy of KH176 in subjects with a genetically confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G mutatio... | ||
Medical condition: A genetically confirmed mitochondrial desoxyribonucleic acid (DNA) tRNALeu(UUR) m.3243A>G mutation (including but not limited to MELAS. MIDD and mixed phenotypes. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001489-41 | Sponsor Protocol Number: P00003466 | Start Date*: 2018-07-02 | |||||||||||
Sponsor Name:Karolinska Universitetssjukhuset | |||||||||||||
Full Title: Radiation- and alkylator-free hematopoietic cell transplantation for bone marrow failure due to dyskeratosis congenita / telomere disease | |||||||||||||
Medical condition: Dyskeratosis congenita / telomere disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022598-32 | Sponsor Protocol Number: ABE4955g | Start Date*: 2011-07-13 | |||||||||||
Sponsor Name:Genentech Inc | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, PHASE II STUDY TO EVALUATE THE IMPACT OF MABT5102A ON BRAIN AMYLOID LOAD AND RELATED BIOMARKERS IN PATIENTS WITH MILD TO... | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021926-37 | Sponsor Protocol Number: ABE4869g | Start Date*: 2011-07-25 | |||||||||||
Sponsor Name:Genentech Inc | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MABT5102A IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006997-27 | Sponsor Protocol Number: CRAD001M2301 | Start Date*: 2011-06-01 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A randomized, double-blind, placebo-controlled study of RAD001 in the treatment of patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC) | ||
Medical condition: This study will evaluate the antitumor activity of RAD001 versus placebo in patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC). | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) IT (Completed) GB (Completed) DE (Completed) NL (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.